MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Gemin X announced today that a report published in the online version of the journal Proceedings of the National Academy of Sciences (PNAS) confirmed the Bcl-2-mediated mechanism of action of its lead compound, obatoclax (GX15-070), demonstrating that it specifically disrupts the survival of cancer cells as a result of inhibiting the Bcl-2 pro-survival protein Mcl-1. This mechanism of action allows obatoclax to overcome Mcl-1-mediated cancer cell resistance to apoptosis, or programmed cell death. Obatoclax is a novel, small molecule candidate in Phase 2 trials in multiple cancer indications that is specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.
